Skip to main content

Table 1 Description of study cohort and assessment of potential risk factors for CDI

From: Management of a cluster of Clostridium difficile infections among patients with osteoarticular infections

   CDI cases Non-RT027 RT027 p valuesa
Median age   73.08 (range 54–87) 71.63 74.13  
Sex female 16 6 10 0.41
male 10 5 5 0.41
Hospitalization on septic/non-septic ward septic ward 21 7d 14 0.04
all other wards 5 4 b,c 1  
Primary diagnosis periprosthetic infection 19 8 11 0.81
soft tissue / wound infection 4 1 3  
spondylitis 2 2 0  
osteomyelitis 1 0 1  
Co-morbidities renal insufficiency 12 4 8 0.41
diabetes 11 5 6  
pneumonia 1 0 1  
neoplasm 2 1 1  
hepatic disease 2 1 1  
Antimicrobial therapy aminopenicillins 4 1 3 0.72
ureidopenicillins 6 2 4 0.42
fluoroquinolones 9 3 6 0.27
cephalosporins 13 5 8 0.24
clindamycin 7 3 4 0.81
rifampicin 13 6 7 0.69
Gastric acid suppressors proton pump inhibitors/H2 blockers 25 11 14  
Severity factors creatinine (>1.5x103g/L) 7 3 4 0.99
leukocytosis (>1.5x109/L) 10 4 6 0.93
Antimicrobial CDI treatment
First episode metronidazole po. 18 8 10  
vancomycin po. 1 0 1  
metronidazole iv. vancomycin po. 2 unknown unknown  
fidaxomicin po. 4 1 3  
colectomy 1 0 1  
no treatment 1 0 1  
Recurrence vancomycin po. 5 2 3  
metronidazole iv. + vancomycin po. 1 0 1  
fidaxomicin po. 3 1 2  
fecal biota transplantation 1 0 1  
Clinical outcome cure 15 9 6 0.21
recurrence 10 3 7 0.37
death within 6 months 4 0 4 0.13
death CDI attributed 1 0 1  
death CDI contributed 3 0 3  
  1. a p values were determined with Fisher’s exact Test
  2. b Sequence type ST 6
  3. c Sequence types ST3, 14, 15
  4. d Sequence types ST3, 6, 8, 14, 92, and two unknown strains